It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Nearly half of all pregnancies are unintended; thus, existing family planning options are inadequate. For men, the only choices are condoms and vasectomy, and most current efforts to develop new contraceptives for men impact sperm development, meaning that contraception requires months of continuous pretreatment. Here, we provide proof-of-concept for an innovative strategy for on-demand contraception, where a man would take a birth control pill shortly before sex, only as needed. Soluble adenylyl cyclase (sAC) is essential for sperm motility and maturation. We show a single dose of a safe, acutely-acting sAC inhibitor with long residence time renders male mice temporarily infertile. Mice exhibit normal mating behavior, and full fertility returns the next day. These studies define sAC inhibitors as leads for on-demand contraceptives for men, and they provide in vivo proof-of-concept for previously untested paradigms in contraception; on-demand contraception after just a single dose and pharmacological contraception for men.
Half of all pregnancies are unintended; thus, existing family planning options are inadequate. This proof-of-concept study validates an on-demand contraception strategy for men, showing high effectiveness in quickly and temporarily reducing male fertility in mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Weill Cornell Medicine, Department of Pharmacology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
2 Tri-Institutional Therapeutics Discovery Institute, New York, USA (GRID:grid.511444.1)
3 Tri-Institutional Therapeutics Discovery Institute, New York, USA (GRID:grid.511444.1); Weill Cornell Medicine, Department of Physiology and Biophysics, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
4 University of Bayreuth, Department of Biochemistry, Bayreuth, Germany (GRID:grid.7384.8) (ISNI:0000 0004 0467 6972)
5 Memorial Sloan Kettering Cancer Center, and The Rockefeller University, Laboratory of Comparative Pathology, Weill Cornell Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
6 Weill Cornell Medicine, Department of Pharmacology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Tri-Institutional Therapeutics Discovery Institute, New York, USA (GRID:grid.511444.1)